Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 3/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.31 |
| ▸ | KDM6B | O15054 | 2/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL1287287 | 1.00 | LMNA (0.41) | LMNAEGLN1ALKBH5SUCNR1SLC15A2 | |
| Oxalic Acid SCHEMBL28173980 | 0.83 | — | — | |
| Tetrazole SCHEMBL27840716 | 0.79 | FFAR3 (0.33) | — | |
| Fumaric Acid SCHEMBL6454283 | 0.77 | TSHR (0.41) | EGLN1KDM4ETSHR | |
| Maleic Acid SCHEMBL6454273 | 0.77 | TSHR (0.41) | EGLN1KDM4ETSHR | |
| Benzene SCHEMBL8551907 | 0.77 | — | — | |
| Tetrazole SCHEMBL3521152 | 0.74 | — | — | |
| Tetrazole SCHEMBL6266187 | 0.74 | — | — | |
| Tetrazole SCHEMBL6130450 | 0.74 | — | — | |
| Tetrazole SCHEMBL7089941 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4164651-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR USE IN THE TREATMENT OF CORONAVIRAL INFECTIONS | METRIOPHARM AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-4125802-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY | METRIOPHARM AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250255891-A1 | PHARMACEUTICAL COMPOSITION INJECTABLE INTO URINARY TRACT ORGAN CAVITY FOR PREVENTION OR TREATMENT OF UROTHELIAL CANCER | NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2025-08-14 | — | — | US | disclosed |
| US-20250249025-A1 | DRUG DELIVERY CARRIER UTILIZING PROPERTY OF D-ALLOSE BEING UPTAKEN BY CANCER CELL, DRUG DELIVERY METHOD, AND COMPOSITION FOR TREATING RENAL CELL CARCINOMA | NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY (JP) | 2025-08-07 | — | — | US | disclosed |
| US-20250171735-A1 | BIOACTIVE COATING MATERIAL | ZETA SCIENCE GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025067689-A1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR THE TREATMENT OF INFECTIONS WITH AN RNA VIRUS | METRIOPHARM AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025046109-A1 | COMBINATION OF ELDERBERRY EXTRACT AND QUININE FOR THE PROPHYLAXIS AND TREATMENT OF RNA VIRUS INFECTIONS | IPRONA LANA AG/SPA (IT) | 2025-03-06 | — | — | WO | disclosed |
| US-12221620-B2 | Bioactive coating material | ZETA SCIENCE GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| EP-4142728-B1 | 6'-METHOXYCINCHONAN-9-OLS FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | IMMUNOLOGIK GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| CN-115427076-B | Human deubiquitinase inhibitors for the treatment of coronavirus infections | 免疫学有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20140050793-A1 | Novel Compositions for Inhibiting Virus Entry and Promoting Virolysis, and Methods Thereof | DREXEL UNIVERSITY (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012143477-A2 | ANTICANCER FUSION PROTEIN | ADAMED SP. Z O.O. (PL) | 2012-10-26 | — | — | WO | disclosed |
| EP-2471802-A1 | Phosphoramidates of monosaccharides | Bioiberica, S.A. (ES) | 2012-07-04 | — | — | EP | disclosed |
| CN-101072566-B | Pharmaceutical compositions for transdermal delivery | FORHUMAN TECH CO LTD | 2012-05-16 | — | — | CN | disclosed |
| WO-2012048033-A2 | NOVEL COMPOSITIONS FOR INHIBITING VIRUS ENTRY AND PROMOTING VIROLYISIS, AND METHODS THEREOF | DREXEL UNIVERSITY (US) | 2012-04-12 | — | — | WO | disclosed |
| CN-101939335-A | Antigen binding polypeptides against cartilage degeneration | DELENEX THERAPEUTICS AG | 2011-01-05 | — | — | CN | disclosed |
| CN-1496271-B | Method for treating diseases accompanied by reduction in expression of AOP-1 gene or AOP-1, and therapeutic agent for the diseases | DAIICHI SUNTORY PHARMACEUTICAL CO LTD | 2010-04-28 | — | — | CN | disclosed |
| CN-101072566-A | Pharmaceutical compositions for transdermal delivery | FORHUMAN TECH CO LTD (KR) | 2007-11-14 | — | — | CN | disclosed |
| CN-101032548-A | Traditional Chinese medicine composition for treating and inhibiting prostate cancer and inhibiting prostate enlargement | GUODING BIOTECHNOLOGY CO LTD (CN) | 2007-09-12 | — | — | CN | disclosed |
| CN-1496271-A | Method for treating diseases accompanied by reduction in expression of AOP-1 gene or AOP-1, and therapeutic agent for the diseases | ��һ��������ҩ��ʽ���� | 2004-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050793-A1 | Novel Compositions for Inhibiting Virus Entry and Promoting Virolysis, and Methods Thereof | ZC3HAV1, ZC3HAV1L, CPN1 | LMNA 3357/4885EGLN1 3951/4885ALKBH5 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.